Literature DB >> 16945583

Group V sPLA2: classical and novel functions.

Barbara Balestrieri1, Jonathan P Arm.   

Abstract

Group V sPLA(2) is unique among the family of secretory sPLA(2) enzymes in being able to bind to cell membranes through both interfacial-binding and through binding to proteoglycan. The function of group V sPLA(2) as an enzyme and its cross-talk with cPLA(2)alpha in initiating eicosanoid generation is well documented. Evidence, though, is emerging on the ability of this molecule to act as a regulator of several intracellular and extracellular pathways independently of its ability to provide arachidonic acid for eicosanoid generation, acting within the cell or as a secreted enzyme. In this article we will provide an overview of the properties of the enzyme and how they relate to our current understanding of its function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16945583     DOI: 10.1016/j.bbalip.2006.07.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  18 in total

1.  Factors controlling vascular permeability: transmitting mechanical signals. Focus on "Mechanical induction of group V phospholipase A₂ causes lung inflammation and acute lung injury".

Authors:  Judy Creighton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-06-28       Impact factor: 5.464

Review 2.  Multiple roles of phospholipase A2 during lung infection and inflammation.

Authors:  Bryan P Hurley; Beth A McCormick
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

3.  Group V secretory phospholipase A2 is involved in macrophage activation and is sufficient for macrophage effector functions in allergic pulmonary inflammation.

Authors:  Shin Ohta; Mitsuru Imamura; Wei Xing; Joshua A Boyce; Barbara Balestrieri
Journal:  J Immunol       Date:  2013-05-06       Impact factor: 5.422

4.  Group V secretory phospholipase A2 reveals its role in house dust mite-induced allergic pulmonary inflammation by regulation of dendritic cell function.

Authors:  Giorgio Giannattasio; Daisuke Fujioka; Wei Xing; Howard R Katz; Joshua A Boyce; Barbara Balestrieri
Journal:  J Immunol       Date:  2010-09-03       Impact factor: 5.422

5.  Epigenetic control of group V phospholipase A2 expression in human malignant cells.

Authors:  Mario Menschikowski; Albert Hagelgans; Brit Nacke; Carsten Jandeck; Olga A Mareninova; Liana Asatryan; Gabriele Siegert
Journal:  Tumour Biol       Date:  2015-12-29

6.  Biallelic mutations in PLA2G5, encoding group V phospholipase A2, cause benign fleck retina.

Authors:  Panagiotis I Sergouniotis; Alice E Davidson; Donna S Mackay; Eva Lenassi; Zheng Li; Anthony G Robson; Xu Yang; Jaimie Hoh Kam; Timothy W Isaacs; Graham E Holder; Glen Jeffery; Jonathan A Beck; Anthony T Moore; Vincent Plagnol; Andrew R Webster
Journal:  Am J Hum Genet       Date:  2011-12-01       Impact factor: 11.025

7.  Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes.

Authors:  Georgia Antonopoulou; Efrosini Barbayianni; Victoria Magrioti; Naomi Cotton; Daren Stephens; Violetta Constantinou-Kokotou; Edward A Dennis; George Kokotos
Journal:  Bioorg Med Chem       Date:  2008-11-01       Impact factor: 3.641

8.  Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.

Authors:  Constantinos Baskakis; Victoria Magrioti; Naomi Cotton; Daren Stephens; Violetta Constantinou-Kokotou; Edward A Dennis; George Kokotos
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

9.  Synthesis of 2-oxoamides based on sulfonamide analogs of gamma-amino acids and their activity on phospholipase A2.

Authors:  Georgia Antonopoulou; Victoria Magrioti; Daren Stephens; Violetta Constantinou-Kokotou; Edward A Dennis; George Kokotos
Journal:  J Pept Sci       Date:  2008-10       Impact factor: 1.905

10.  Group V secretory phospholipase A2 modulates phagosome maturation and regulates the innate immune response against Candida albicans.

Authors:  Barbara Balestrieri; Akiko Maekawa; Wei Xing; Michael H Gelb; Howard R Katz; Jonathan P Arm
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.